Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib in Familial Adenomatous Polyposis (FAP)
NCT00140894Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2002
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in familial adenomatous polyposis (FAP) comparing Rofecoxib with Placebo (2 arms). Primary endpoints: Number and average size of rectal polyps and Safety and tolerability. Started Aug 2002; status: terminated.
02
Drugs
rofecoxib
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT00140894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140894.